Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with nab-TPC vs GP in NPC
NCT06669611Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and capecitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 15 months. Started Nov 2024; status: recruiting.
02
Drugs
paclitaxelcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06669611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669611.